Arrowhead Pharmaceuticals旗下Plozasiran在Shasta-3和Shasta-4试验中实现中位甘油三酯降低79%和81%

美股速递
Jul 22

Arrowhead Pharmaceuticals公司宣布,其研究性药物Plozasiran在两项关键临床试验——Shasta-3与Shasta-4中,取得了显著成果。数据显示,该药物分别实现了79%和81%的中位甘油三酯降低率,展现出强大的治疗潜力。

这一积极结果标志着公司在心血管代谢疾病治疗领域的重要进展,也为Plozasiran的后续开发奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10